Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Gail_McIntyre
|
| gptkbp:clinicalTrialPhase |
Phase 3 trial for batiraxcept in ovarian cancer
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
targeted therapies for cancer
|
| gptkbp:focusesOn |
oncology
therapeutics |
| gptkbp:formerName |
gptkb:Aravive_Biologics,_Inc.
|
| gptkbp:foundedYear |
2008
|
| gptkbp:headquartersLocation |
gptkb:Houston,_Texas,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aravive
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:batiraxcept
|
| gptkbp:status |
gptkb:public_company
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_ARAV
|
| gptkbp:website |
https://www.aravive.com/
|
| gptkbp:bfsParent |
gptkb:Srinivas_Akkaraju
gptkb:Versartis |
| gptkbp:bfsLayer |
7
|